
==== Front
Hypertens Res
Hypertens Res
Hypertension Research
0916-9636
1348-4214
Springer Nature Singapore Singapore

39039284
1779
10.1038/s41440-024-01779-4
Article
An outcome-driven threshold for pulse pressure amplification
Huang Qi-Fang 1
An De-Wei 123
Aparicio Lucas S. 4
Cheng Yi-Bang 1
Wei Fang-Fei 25
Yu Yu-Ling 23
Sheng Chang-Sheng 1
Yang Wen-Yi 6
Niiranen Teemu J. 7
Boggia José 8
Stolarz-Skrzypek Katarzyna 9
Tikhonoff Valérie 10
Gilis-Malinowska Natasza 11
Wojciechowska Wiktoria 9
Casiglia Edoardo 10
Narkiewicz Krzysztof 11
Filipovský Jan 12
Kawecka-Jaszcz Kalina 9
Nawrot Tim S. 3
Wang Ji-Guang 1
Li Yan liyanshcn@163.com

1
Staessen Jan A. jan.staessen@appremed.org

1213
The International Database of Central Arterial Properties for Risk Stratification (IDCARS) InvestigatorsAparicio Lucas S. 14
Barochiner Jessica 14
Mujaj Blerim 15
Thijs Lutgarde 15
Staessen Jan A. 15
Wei Fang-Fei 15
Yang Wen-Yi 15
Zhang Zhen-Yu 15
An De-Wei 16
Cheng Yi-Bang 16
Guo Qian-Hui 16
Huang Jian-Feng 16
Huang Qi-Fang 16
Kang Yuan-Yuan 16
Li Yan 16
Liu Chang-Yuan 16
Sheng Chang-Sheng 16
Wang Ji-Guang 16
Wang Ying 16
Zhang Dong-Yan 16
Zhang Wei 16
Filipovský Jan 17
Seidlerová Jitka 17
Juhanoja Eeva P. 18
Jula Antti M. 18
Lindroos Annika S. 18
Niiranen Teemu J. 18
Sivén Sam S. 18
Casiglia Edoardo 19
Pizziol Alessandra 19
Tikhonoff Valérie 19
Chori Babangida S. 20
Danladi Benjamin 20
Odili Augustine N. 20
Oshaju Henry 20
Kucharska Wiesława 21
Kunicka Katarzyna 21
Gilis-Malinowska Natasza 21
Narkiewicz Krzysztof 21
Sakiewicz Wojciech 21
Swierblewska Ewa 21
Kawecka-Jaszcz Kalina 22
Stolarz-Skrzypek Katarzyna 22
Mels Catharina M. C. 23
Kruger Ruan 23
Mokwatsi Gontse G. 23
Schutte Aletta E. 23
Norton Gavin R. 24
Woodiwiss Angela 24
Ackermann Daniel 25
Bochud Murielle 25
Ehret Georg 25
Álvarez-Vaz Ramón 26
Rios Anna C. 26
Carusso Florencia 26
Sottolano Mariana 26
Boggia José 26
Borgarello Luciana 26
Robaina Sebastián 26
Moliterno Paula 26
Noboa Oscar 26
Olascoaga Alicia 26
da Rosa Alicia 26
Krul Nadia 26
Pécora Matias 26

1 grid.16821.3c 0000 0004 0368 8293 Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 grid.518490.1 Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium
3 https://ror.org/05f950310 grid.5596.f 0000 0001 0668 7884 Research Unit Environment and Health, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium
4 https://ror.org/00bq4rw46 grid.414775.4 0000 0001 2319 4408 Servicio de Clínica Médica, Sección Hipertensión Arterial, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
5 https://ror.org/037p24858 grid.412615.5 0000 0004 1803 6239 Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong China
6 https://ror.org/04a46mh28 grid.412478.c 0000 0004 1760 4628 Department of Cardiology, Shanghai General Hospital, Shanghai, China
7 grid.410552.7 0000 0004 0628 215X Department of Chronic Disease Prevention, Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
8 grid.11630.35 0000000121657640 Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay
9 https://ror.org/03bqmcz70 grid.5522.0 0000 0001 2337 4740 First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
10 https://ror.org/00240q980 grid.5608.b 0000 0004 1757 3470 Department of Medicine, University of Padua, Padua, Italy
11 https://ror.org/019sbgd69 grid.11451.30 0000 0001 0531 3426 Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland
12 https://ror.org/024d6js02 grid.4491.8 0000 0004 1937 116X Faculty of Medicine, Charles University, Pilsen, Czech Republic
13 https://ror.org/05f950310 grid.5596.f 0000 0001 0668 7884 Biomedical Sciences Group, Faculty of Medicine, University of Leuven, Leuven, Belgium
14 Buenos Aires, Argentina
15 Noordkempen, Belgium
16 Jing Ning, China
17 Pilsen, Czech Republic
18 Finn-Home, Finland
19 Padova, Italy
20 Abuja, Nigeria
21 Gdańsk, Poland
22 Kraków, Poland
23 Potchefstroom, South Africa
24 Johannesburg, South Africa
25 Bern, Geneva and Lausanne Switzerland
26 Montevideo, Uruguay
22 7 2024
22 7 2024
2024
47 9 24782488
6 2 2024
20 5 2024
8 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Pulse pressure amplification (PPA) is the brachial-to-aortic pulse pressure ratio and decreases with age and cardiovascular risk factors. This individual-participant meta-analysis of population studies aimed to define an outcome-driven threshold for PPA. Incidence rates and standardized multivariable-adjusted hazard ratios (HRs) of cardiovascular and coronary endpoints associated with PPA, as assessed by the SphygmoCor software, were evaluated in the International Database of Central Arterial Properties for Risk Stratification (n = 5608). Model refinement was assessed by the integrated discrimination (IDI) and net reclassification (NRI) improvement. Age ranged from 30 to 96 years (median 53.6). Over 4.1 years (median), 255 and 109 participants experienced a cardiovascular or coronary endpoint. In a randomly defined discovery subset of 3945 individuals, the rounded risk-carrying PPA thresholds converged at 1.3. The HRs for cardiovascular and coronary endpoints contrasting PPA < 1.3 vs ≥1.3 were 1.54 (95% confidence interval [CI]: 1.00–2.36) and 2.45 (CI: 1.20–5.01), respectively. Models were well calibrated, findings were replicated in the remaining 1663 individuals analyzed as test dataset, and NRI was significant for both endpoints. The HRs associating cardiovascular and coronary endpoints per PPA threshold in individuals <60 vs ≥60 years were 3.86 vs 1.19 and 6.21 vs 1.77, respectively. The proportion of high-risk women (PPA < 1.3) was higher at younger age (<60 vs ≥60 years: 67.7% vs 61.5%; P < 0.001). In conclusion, over and beyond common risk factors, a brachial-to-central PP ratio of <1.3 is a forerunner of cardiovascular coronary complications and is an underestimated risk factor in women aged 30–60 years. Our study supports pulse wave analysis for risk stratification.

Keywords

Pulse pressure amplification, Waveform analysis, Cardiovascular risk, Population science
issue-copyright-statement© The Japanese Society of Hypertension 2024
==== Body
pmcIntroduction

Pulse pressure (PP), the difference between systolic and diastolic blood pressure (BP), oscillates around mean arterial pressure and increases from the central to the peripheral arteries, causing PP amplification (PPA) [1–5]. PPA is most commonly represented by the ratio of brachial-to-aortic PP [1–5]. Over the human lifespan, PPA decreases as a consequence of arterial stiffening associated with aging and further promoted by hypertension, dyslipidemia, diabetes, and chronic kidney disease [4, 6]. Stiffening of the central elastic arteries leads to the earlier return of backward waves from peripheral reflection sites [1, 5], thereby increasing central systolic pressure, so that the ratio of brachial-to-aortic PP decreases. Among healthy, normotensive individuals enrolled in the Anglo-Cardiff Collaborative Trial (ACCT), PPA decreased from 1.72 in teenagers to 1.25 in octogenarians [7]. In populations [2] and patients [8], arterial stiffening, as captured by lower PPA, is associated with higher cardiovascular risk [2, 3], coronary artery diseases [9], deterioration of renal function [8], and mortality [3]. However, few prospective studies focused on the incidence of major cardiovascular complications in relation to PPA. To the best of our knowledge, there is therefore no published outcome-driven PPA threshold, which might alert clinicians for the risk of cardiovascular complications related to falling PPA. To address this issue, the current individual-participant level meta-analysis defined, calibrated and validated an outcome-driven threshold for PPA, using the International Database of Central Arterial Properties for Risk Stratification (IDCARS) [10].

Methods

Study participants

The study protocol paper describes the construction of the IDCARS database [10]. The longitudinal studies extracted from the IDCARS resource qualified for the current analysis, if information on brachial and central BP and cardiovascular risk factors was available at baseline, if the arterial pulse waveform had been measured, if follow-up included both fatal and nonfatal endpoints, if study reports were published in peer-reviewed journals, and if the study participants were representative for a population. All studies complied with the Helsinki Declaration on research in humans [11] and were approved by the competent Institutional Review Boards. Participants provided written informed consent. All data were stripped from personal identifiers, and if required by national legislations, additional ethical clearance was obtained. Supplementary Table S1 lists cohort-specific information on the catchment area, sampling strategies, timeframes of recruitment and follow-up, and initial participation rates. Enrolment took place from 1985 until 2015. For the present analysis, baseline refers to the first measurement of central and peripheral BP along with cardiovascular risk factors (October 2000 until February 2016). Across studies, the last follow-up took place from October 2012 to December 2018 (Supplementary Table S1). Of 6650 IDCARS participants qualifying for analysis, we excluded 1042 because they were younger than 30 years without endpoints (n = 954), peripheral PP was >130 mmHg (n = 10), central systolic BP was <70 mmHg (n = 1) or >230 mmHg (n = 1), central diastolic BP was >150 mmHg (n = 1) or <55 mmHg (n = 15), or because the pulse wave analysis was missing (n = 60). This left 5608 participants for statistical analysis.

Pulse wave analysis

Brachial BP, measured immediately prior to the hemodynamic assessment after participants had rested for 5 up to 15 min in the supine position, was the average of two consecutive readings. Experienced observers recorded the radial arterial waveform at the dominant arm during an 8-s period by applanation tonometry. They used a high-fidelity SPC-301 micromanometer (Millar Instruments Inc., Houston, TX), interfaced with a SphygmoCor CvMS device and a laptop computer running SphygmoCor software (AtCor Medical Inc., Itasca, IL). Recordings were discarded, if systolic or diastolic variability of consecutive waveforms exceeded 5% or if the amplitude of the pulse wave signal was below 80 mV, or if the operator index was <70%. From the radial signal, the SphygmoCor software reconstructs the aortic pulse wave by means of a validated generalized transfer function [12]. Estimates of central blood pressure were calibrated on brachial systolic and diastolic BP. PPA was the brachial-to-aortic PP ratio.

Ascertainment of endpoints

We ascertained the incidence of fatal and nonfatal endpoints from the appropriate sources in each country. The primary endpoint was a composite cardiovascular outcome consisting of cardiovascular mortality, sudden death and nonfatal endpoints, including myocardial infarction, heart failure, stroke, and coronary arterial revascularization. The coronary endpoint comprised sudden death and fatal and nonfatal myocardial infarction and coronary revascularization. The endpoints are listed in Supplementary Table S2. All endpoints were validated against hospital files or medical records held by primary care physicians or specialists. Only the first event within each category was considered in the analysis of outcome.

Statistical analysis

Statistical methods are described in detail in the online-only Data Supplement (pp. 2–5). In exploratory analyses, incidence rates of endpoints were tabulated by tertiles of the PPA distribution, while applying the direct method for standardizing rates for cohort, sex and age (<40, 40–59, ≥60 years). The cumulative incidence of the cardiovascular and coronary endpoints was plotted, while accounting for cohort, sex, age and heart rate.

Multivariable-adjusted Cox models accounted for cohort (random effect), sex, age, heart rate, body mass index, smoking and drinking, the total-to-HDL serum cholesterol ratio, the glomerular filtration rate estimated from serum creatinine by the chronic kidney disease epidemiology collaboration equation [13], antihypertensive drug intake, history of cardiovascular disease and diabetes. The proportional hazards assumption was checked by the Kolmogorov-type supremum test.

After stratification for sex, median age (53.6 years) and cohorts (n = 9; Supplementary Table S1), a random function was applied to subdivide the total IDCARS study population (n = 5608) into a discovery (n = 3945) and replication (n = 1663) sample. The size of the discovery dataset required 171 cardiovascular endpoints to demonstrate a difference between high-risk (above PPA risk threshold) and low-risk (below PPA risk thresholds) individuals with the α-level and power set at 0.05 and 0.80, respectively [14]. The default significance throughout the current study was a two-tailed α-level of ≤0.05 with the SE to compute two-sided confidence intervals [CI] set at 1.96. However, given the prior probability in the discovery dataset, in the replication analysis, the α-level was a one-tailed level of ≤0.05 and the SE to compute CIs was 1.65.

To determine an operational threshold for PPA in the discovery dataset, a two-pronged strategy [15, 16] was applied using Cox regression. First, multivariable-adjusted HRs were computed for 0.1 increments in PPA from the 10th to the 90th percentile of the PPA distribution. These HRs expressed the risk in participants, whose PPA exceeded the cut-off point vs the average risk in the whole population. The HRs with CIs were plotted as function of increasing PPA thresholds to assess at which PPA level the upper 95% confidence limit of the HRs crossed unity, signifying decreased risk [15]. Next, PPA thresholds were obtained by determining the PPA levels yielding a 5-year risk equivalent to the risk associated with a brachial systolic BP of 120-, 130-, 140- and 160 mmHg [16]. Model calibration was evaluated by comparing the predicted risk against overoptimism-corrected Kaplan–Meier estimates in PPA quintiles. The performance of PPA in risk stratification was assessed from 2-by-2 tables providing specificity, sensitivity and related statistics, the area (AUC) under the receiver operating curve (ROC), the area (AUC) under the receiver operating curve, and by the integrated discrimination improvement (IDI) and the net reclassification improvement (NRI) [17].

Finally, subgroup analyses were conducted in participants stratified by sex, age (<60 vs ≥60 years), median systolic BP (<130 vs ≥130 mmHg) and antihypertensive treatment status. To compare relative risk across these strata, deviation from mean coding [18] was applied. In a further sensitivity analysis, models for the coronary endpoint were additionally adjusted for diastolic BP, the driving force of the coronary circulation.

Results

Baseline characteristics of participants

Table 1 lists the main characteristics of the 5608 analyzed participants. Mean age at baseline was 54.2 years. Among all participants, 2988 (53.3%) had hypertension, 1946 (34.7%) were on antihypertensive treatment. Of 1946 patients reporting information on antihypertensive drugs, 672 (34.5%) and 1274 (65.5%) were taking a single agent or combination therapy, respectively. Drug classes taken were diuretics in 648 (33.3%) patients, β-blockers in 747 (38.4%), inhibitors of the renin–angiotensin system in 1184 (60.8%), and vasodilators in 833 (42.8%). Among the 5608 study participants (Table 1), 3035 (54.1%) were women. The PPA distributions is shown in Supplementary Fig. S1. The association between PPA and age is shown in Supplementary Fig. S2. Compared to women, more men reported smoking cigarettes (33.7% vs 10.2%) or consuming alcoholic beverages (75.4% vs 28.9%).Table 1 Baseline characteristics of participants

Characteristic	Discovery	Replication	All	
Number in group	3945	1663	5608	
Number with characteristic (%)	
 Ethnicity	
   White Europeans	1684 (42.7)	701 (42.2)	2385 (42.5)	
   Chinese	1279 (32.4)	544 (32.7)	1823 (32.5)	
   South Americans	982 (24.9)	418 (25.1)	1400 (25.0)	
  Women	2134 (54.1)	901 (54.2)	3035 (54.1)	
  Hypertension	2076 (52.6)	912 (54.8)	2988 (53.3)	
   Treated hypertension	1346 (34.1)	600 (36.1)	1946 (34.7)	
  Diabetes mellitus	246 (6.2)	93 (5.6)	339 (6.0)	
  History of cardiovascular disease	555 (14.1)	238 (14.3)	793 (14.1)	
  Current smoking	853 (21.6)	326 (19.6)	1179 (21.0)	
  Drinking alcohol	1990 (50.4)	826 (49.7)	2816 (50.2)	
Mean of characteristic (SD)	
  Age, y	54.2 (14.5)	54.2 (14.1)	54.2 (14.4)	
  Body mass index, kg/m2	25.8 (4.9)	25.9 (4.8)	25.8 (4.8)	
 Brachial blood pressure, mmHg	
   Systolic	134.1 (20.9)	134.1 (21.2)	134.1 (21.0)	
   Diastolic	80.0 (10.6)	80.5 (10.8)	80.1 (10.7)	
   Pulse pressure	54.1 (16.3)	53.6 (16.3)	53.9 (16.3)	
 Central blood pressure, mmHg	
   Systolic	123.7 (21.0)	123.9 (21.5)	123.7 (21.2)	
   Diastolic	81.0 (10.8)	81.5 (11.0)	81.2 (10.9)	
   Pulse pressure	42.6 (16.0)	42.4 (16.2)	42.6 (16.1)	
  Heart rate, beats per min	65.5 (11.4)	65.6 (11.5)	65.5 (11.4)	
 Total serum cholesterol, mg/dL	194.8 (38.6)	196.8 (39.8)	195.4 (38.9)	
 HDL serum cholesterol, mg/dL	57.4 (15.2)	57.6 (15.2)	57.5 (15.2)	
 Total-to-HDL cholesterol ratio	3.6 (1.1)	3.6 (1.1)	3.6 (1.1)	
 Glomerular filtration rate (mL/min/1.73 m2)	82.4 (19.9)	82.6 (19.1)	82.5 (19.6)	
 Blood glucose, mg/dL	90.6 (18.8)	90.9 (20.2)	90.7 (19.2)	
 Pulse pressure amplification	1.31 (0.19)	1.31 (0.19)	1.26 (1.16–1.42)	
 Median follow-up (IQR), years	4.1 (3.6–6.9)	4.2 (3.6–7.5)	4.1 (3.6–6.9)	
After stratification for sex, median age (53.6 years) and cohorts, a random function was applied to subdivide the total IDCARS study population into a discovery and replication sample, which were well matched (P ≥ 0.09 for all characteristics). Current smoking was inhaling tobacco smoke on a daily basis. Drinking alcohol was the occasional or daily consumption of alcoholic beverages. Diabetes mellitus was use of anti-diabetic drugs, fasting blood glucose ≥126 mg/dL, random blood glucose ≥200 mg/dL, a self-reported diagnosis, or diabetes documented in practice or hospital records. Hypertension was a brachial blood pressure of ≥140 mmHg systolic or ≥90 mmHg diastolic, or use of antihypertensive drugs. The glomerular filtration rate was derived from serum creatinine using the chronic kidney disease epidemiology collaboration formula

HDL high-density lipoprotein

Incidence of endpoints

Over a median follow-up of 4.1 years (interquartile range (IQR): 3.6–6.9 years; 5th–95th percentile interval: 2.2–12.1 years), of 5608 participants, 255 (4.55%) experienced a cardiovascular endpoint and 109 (1.94%) a coronary endpoint, resulting in rates of 9.59 events per 1000 person-years (confidence interval (CI): 8.82–10.4) and 4.05 events per 1000 person-years (CI: 3.53–4.57), respectively. Across tertiles of the PPA distribution, the crude rates of cardiovascular and coronary endpoints decreased with higher PPA category (Supplementary Table S3). Figure 1 shows the cumulative incidence of the cardiovascular and coronary endpoints by PPA tertiles with adjustment for cohort (random effect), sex and age. Given that in the whole study population, PPA was a risk factor, in the next step of the analysis, we first determined an outcome-driven threshold in the discovery sample.Fig. 1 Cumulative incidence of the cardiovascular and coronary endpoints by tertiles of pulse pressure amplification. Cumulative incidence of the cardiovascular (A) and coronary (B) endpoints was derived by Cox regression with adjustment for cohort, sex and age. P values denote the overall significance of the difference between the PPA categories. Vertical lines denote the SE. Tabulated data are the number of participants at risk at 5-year intervals

Analysis of the discovery sample

Multivariable-adjusted HRs were plotted against PPA thresholds stepwise increasing by 0.1 over the 10th–90th percentile range of the PPA distribution (Fig. 2A, B). These multivariable-adjusted HRs expressed the 5-year risks of cardiovascular and coronary endpoints associated with successively increasing PPA thresholds compared to the average risk in the discovery cohort. The upper 95% confidence limit of the HRs crossed unity at a PPA level of 1.28 and 1.26 for the cardiovascular and coronary endpoints, respectively. Furthermore, the PPA thresholds yielding a risk equivalent with a systolic BP of 140 mmHg were 1.28 (CI: 1.19–1.36) and 1.29 (CI: 1.22–1.36) for the cardiovascular and coronary endpoints (Fig. 2C, D). With rounding applied, the PPA thresholds distinguishing between low and high risk of the two endpoints endpoint were <1.3 vs ≥1.3). In the discovery dataset, the adjusted HRs contrasting PPA levels of <1.3 vs ≥1.3 were 1.54 (CI: 1.00–2.36) for the cardiovascular endpoint and 2.45 (CI: 1.20–5.01) for the coronary endpoint (Table 2). These models were well calibrated (Fig. 2E, F). A 1-SD PPA increment in the discovery cohort yielded multivariable-adjusted HRs of 0.74 (CI: 0.26–0.97) and 0.57 (CI: 0.36–0.91) for the cardiovascular and coronary endpoint (Table 2).Fig. 2 Threshold and calibration of pulse pressure amplification (PPA) in the discovery sample including 3945 participants. Hazard ratios (HRs) express the risk at each PPA level relative to the average risk in the whole discovery sample for cardiovascular (A) and coronary endpoints (B). The upper confidence limit crosses unity, denoted by the vertical line, at 1.28 and 1.26 for cardiovascular and coronary endpoints, signifying decreased risk. The PPA levels yielding equivalent 5-year risks compared with a systolic blood pressure of 140 mmHg were 1.28 and 1.29 for the cardiovascular (C) and coronary (D) endpoints, respectively. Model calibration for the cardiovascular (E) and coronary (F) endpoints demonstrated that across PPA quintiles the predicted risk was similar compared with the overoptimism-corrected Kaplan–Meier estimates. All analyses were multivariable adjusted for cohort (random effect), sex, age, body mass index, heart rate, smoking and drinking, total-to-HDL serum cholesterol ratio, estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes

Table 2 Endpoints in relation to PPA per threshold or analyzed as continuously distributed variable

Cohort Endpoint Risk indicator	Ne/Nr	HR (95% CI)	P value	
Discovery (n = 3945)	
 Cardiovascular	
   PPA < 1.3 vs ≥1.3	150/2230 vs 39/1715	1.54 (1.00–2.36)	0.048	
   PPA + 1 SD	189/3945	0.74 (0.56–0.97)	0.031	
 Coronary	
   PPA < 1.3 vs ≥1.3	66/2230 vs 12/1715	2.45 (1.20–5.01)	0.014	
   PPA + 1 SD	78/3945	0.57 (0.36–0.91)	0.018	
Replication (n = 1663)	
 Cardiovascular	
   PPA < 1.3 vs ≥1.3	53/949 vs 13/714	2.02 (1.07–3.78)	0.033	
   PPA + 1 SD	66/1663	0.61 (0.39–0.96)	0.036	
 Coronary	
   PPA < 1.3 vs ≥1.3	25/949 vs 6/714	2.90 (1.18–7.12)	0.025	
   PPA + 1 SD	31/1663	0.61 (0.34–1.11)	0.085	
Models were adjusted for cohort (random effect), sex, age, body mass index, heart rate, smoking and drinking, total-to-HDL serum cholesterol ratio, estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes. Given the prior probability generated in the discovery sample, confidence interval and P values in the replication sample are one-sided

Ne/Nr number of events/of participants at risk

Replication

In the replication population (Table 2), the HRs were similar, but given the prior probability generated in the discovery sample HRs are given with one-sided P values and confidence intervals. However, given the smaller sample size, significance was not reached for the coronary endpoint in the continuous analysis (P = 0.085).

Predictive performance

Supplementary Table S4 lists the performance of the 1.3 PPA threshold in the 5-year risk stratification and the AUC for the continuously distributed PPA. For the cardiovascular and coronary endpoints, the classification estimates derived from 2-by-2 tables were broadly similar in the discovery, replication and the whole dataset with specificity ~0.40 and sensitivity ~0.80. For the continuously distributed PPA, the AUC was around 0.60.

In the discovery and replication sample and in all participants, NRI for the 1.3 PPA threshold was significant, ranging from 16.1 to 33.7% and from 30.8 to 44.9% for the cardiovascular and coronary endpoint, respectively (Table 3). The corresponding NRI estimates in the continuous analysis ranged from 9.26 to 22.7% and from 21.5 to 30.2%. For both endpoints in the per threshold as well as the continuous analyses IDI did not reach significance.Table 3 Integrated discrimination improvement and net reclassification improvement for pulse pressure amplification

Cohort Endpoint Risk indicator	Integrated discrimination improvement	Net reclassification improvement	
IDI (%)	P	NRI (%)	P	
Discovery (n = 3945)	
 Cardiovascular	
   PPA < 1.3 vs ≥1.3	0.12 (−0.25, 0.50)	0.52	16.1 (1.73, 30.5)	0.028	
   Continuous	0.27 (−0.15, 0.69)	0.21	9.26 (−5.29, 23.8)	0.21	
 Coronary	
   PPA < 1.3 vs ≥1.3	0.41 (−0.41,1.22)	0.33	33.0 (11.9, 54.2)	0.002	
   Continuous	0.40 (−0.47, 1.27)	0.36	21.6 (−0.41, 43.7)	0.054	
Replication (n = 1663)	
 Cardiovascular	
   PPA < 1.3 vs ≥1.3	0.50 (−0.72, 1.71)	0.42	33.7 (10.0, 57.4)	0.005	
   Continuous	0.76 (−0.35, 1.88)	0.18	22.7 (−1.74, 47.1)	0.069	
 Coronary	
   PPA < 1.3 vs ≥1.3	0.89 (−2.08, 3.85)	0.56	44.9 (11.7, 78.2)	0.008	
   Continuous	1.08 (−0.60, 2.76)	0.21	30.2 (−4.45, 64.8)	0.088	
All (n = 5608)	
 Cardiovascular	
   PPA < 1.3 vs ≥1.3	0.16 (−0.20, 0.53)	0.38	15.2 (2.76, 27.6)	0.017	
   Continuous	0.29 (−0.10, 0.68)	0.15	11.8 (−0.70, 24.3)	0.064	
 Coronary	
   PPA < 1.3 vs ≥1.3	0.49 (−0.37, 1.34)	0.26	30.8 (12.7,48.9)	0.001	
   Continuous	0.46 (−0.28, 1.21)	0.22	21.5 (2.85, 40.2)	0.024	
The base model included cohort (random effect), sex, age, body mass index, heart rate, smoking and drinking, total-to-HDL serum cholesterol ratio, estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes. The integrated discrimination improvement (IDI) is the difference between the discrimination slopes of the base model and the base model extended by PPA. The discrimination slope is the difference in predicted probabilities (%) between participants without and with an endpoint. The net reclassification index (NRI) is the sum of the percentages of participants reclassified correctly in individuals without and with an endpoint. IDI and NRI estimates are given with 95% confidence interval

Subgroup and sensitivity analyses

To investigate the consistency of the 1.3 PPA threshold, subgroup analyses were conducted in participants stratified by sex, age (<60 vs ≥60 years), median systolic BP (<130 vs ≥130 mmHg) and antihypertensive treatment status (Fig. 3). With full adjustments applied, the subgroup-by-PPA interaction terms were only significant if participants were categorized by age (P ≤ 0.041). The HRs for a cardiovascular endpoint in the age groups <60 vs ≥60 years were 3.86 (CI: 2.11–7.04) vs 1.19 (CI: 0.75–1.89); the corresponding HRs for the coronary endpoint were 6.21 (CI: 2.50–15.4) vs 1.77 (CI: 0.80–3.89). Among 2006 young (<60 years) low-risk individuals (PPA ≥ 1.3), 815 (40.6%) were women and 129 (6.43%) had isolated systolic hypertension (systolic/diastolic BP: ≥140/<90 mmHg, irrespective of treatment status), while among high-risk (PPA < 1.3) individuals in the same age band these numbers were 1107 (67.7%) and 208 (12.7%), respectively (P < 0.001 for both). Among 423 older (≥60 years) low-risk (PPA ≥ 1.3) participants, 172 (40.2%) were women and 128 (30.3%) had isolated systolic hypertension, while among high-risk (PPA < 1.3) individuals of similar age these numbers were 943 (61.1%) and 612 (39.7%), respectively (P < 0.001 for both). The proportion of women at high risk (PPA < 1.3) was higher in young individuals (<60 vs ≥60 years: 67.7% vs 61.5%; P < 0.001).Fig. 3 Hazard ratios expressing the risk of cardiovascular and coronary endpoints per the 1.3 pulse pressure amplification threshold by subgroups. Hazard ratios, given with 95% confidence interval accounted for cohort (random effect), sex, age, body mass index, heart rate, smoking and drinking, the total-to-HDL serum cholesterol ratio, the estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease and diabetes. Adjustment for sex, age and antihypertensive treatment was omitted, if these variables defined the strata. Squares represent the point estimates of the hazard ratios (HR). Horizontal lines denote 95% confidence interval. NLE/NLR vs NHE/NHR refer to the number of participants with an event/number of participants at risk dichotomized by the threshold of pulse pressure amplification (<1.3 vs ≥1.3, respectively)

In multivariable models additionally adjusted for diastolic BP, the HR for coronary endpoints per threshold in the discovery dataset (PPA < 1.3 vs ≥1.3; number endpoints/individuals at risk: 66/2230 vs 12/1715) was 2.44 (CI: 1.18–5.07; P = 0.017) and 2.79 (CI: 1.10–7.06; P = 0.034) in the replication dataset (25/949 vs 6/714). The corresponding standardized HRs for PPA as continuously distributed variable were 0.57 (CI: 0.35–0.92; P = 0.022) and 0.64 (CI: 0.34–1.20; P = 0.12).

Discussion

According to our reading of the literature, the current study breaks new grounds in two ways. First, it is a prospective population study showing that lower PPA is a risk factor for fatal combined with nonfatal cardiovascular and coronary endpoints. Foremost, it defined and replicated an outcome-driven PPA threshold of 1.3, which particularly below age 60 indicated risk of a cardiovascular or coronary endpoint.

To our knowledge, only three longitudinal population studies reported on the risk associated with PPA. The PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) Study included 1126 participants (77.6% women), who were living in French and Italian nursing homes (mean age: 88.5 years) [3]. During the 2-year follow-up, 247 subjects died, and 228 experienced a major cardiovascular endpoint. A 10% PPA increase was associated with decreases in the event rates amounting to 24% and 17% for total mortality and cardiovascular events, respectively. In the current study, participants with a risk-carrying PPA had a significant higher rate of isolated systolic hypertension (25.8% vs 10.6%) and the HRs contrasting the risk of cardiovascular and coronary endpoints per PPA threshold in individuals <60 vs ≥60 years were 3.86 vs 1.19 and 6.21 vs 1.77, respectively. In the Framingham Heart Study [19], involving 2232 participants (58% women; mean age: 63 years), 151 cardiovascular endpoints occurred over 7.8 years of follow-up. Several indexes reflecting aortic stiffness were predictive, but the standardized multivariable-adjusted hazard ratio for PPA was 0.86 (CI: 0.19–3.82; P = 0.84). The Anglo-Cardiff Collaborative Study involved healthy people and patients with risk factors, such as hypertension, hypercholesterolemia, smoking or diabetes and patients with a history of cardiovascular disease [20]. The 10,613 participants were from 18 to 101 years old (50.8% women). In this report, PPA was expressed as the reciprocal of the traditionally used definition, so that higher values represented individuals with a relatively higher aortic pressure for a given brachial pressure. The aorta-to-brachial PP ratio averaged 0.72 in healthy subjects (1.39 according to the current PPA definition) and was consistently and significantly higher in all other groups (range of means: 0.77–0.80 [1.25–1.30 according to the current definition]) except in smokers (mean value: 0.66 [1.51]).

Pulse pressure amplification and aging

There is large consistency among reports describing the age dependency of PPA. In both women and men, central systolic BP increased more with age than brachial systolic BP (P < 0.001) [21, 22]. The cross-sectional ACCT [7], including 4001 healthy, normotensive individuals, aged 18–90 years, showed that PPA decreased from 1.72 in teenagers to 1.25 in octogenarians. Another study combined volunteers recruited from the community and patients attending an open access clinic for the assessment of cardiovascular risk [23]. Patients with cardiovascular disease, diabetes or on drug treatment were excluded, but not those with hypertension. PPA decreased linearly with age (r = −0.70; P < 0.001) [23]. However, the association with age of the ratio of brachial PP to the non-augmented central PP was not statistically significant (r = 0.10; P = 0.10) [23]. In the current study, the correlation coefficient between PPA and age was −0.50 (P < 0.001, Supplementary Fig. S2).

Clinical relevance

That PPA declines with aging is well established [1–5]. However, among 3642 IDCARS participants younger than 60 years, 1636 (44.9%) had a risk-carrying PPA of <1.3, indicative of early vascular aging and stiffening of the central elastic arteries. Of these high-risk individuals, 1107 (67.7%) were women. Identifications of these individuals at risk is clinically highly relevant, so that cardiovascular risk factors can be timely managed to prevention cardiovascular and coronary complications.

Study limitations

Whilst the IDCARS database is a powerful resource, our study must be interpreted within the context of its potential limitations. First, the reconstruction of the aortic pulse wave from the radial pulse wave using the SphygmoCor technology requires the application of a generalized transfer function, which has been validated [24], but which has also been criticized [25]. For example, the SPC-301 micromanometer interfaced with the SphygmoCor device uses a single pressure sensor for applanation tonometry, but some validation studies of the generalized transfer function have utilized a servo-controlled automated tonometric system based on an arrayed sensor to avoid issues related to a manually operated single sensor [26, 27]. Second, the demographic characteristics, the period of recruitment, and the assessment of endpoint data differed between cohorts. However, the present analyses were adjusted for cohort as a random effect. By design participant-level meta-analyses allow applying the same statistical methods to all contributing cohorts, which is a strong point compared with meta-analyses of summary statistics [28]. Finally, over a median follow-up only 109 coronary endpoints occurred, probably because the low event rate among Chinese (0.49%) vs Europeans (2.64%) and South Americans (2.64%).

Conclusions

Over and beyond common risk factors, low PPA defined as a brachial-to-central PP ratio of <1.3 is a forerunner of cardiovascular and coronary complications and is an underestimated risk factor in women aged from 30 to 60 years. Our study therefore adds to the growing evidence supporting pulse wave analysis for risk stratification in clinical centers where the technology is readily available. If the technology is unavailable, such as for instance in low- and middle-income countries, isolated systolic hypertension can be used as a proxy for PPA [29], in particular in middle-aged and older individuals [30]. However, an important caveat pertains to adolescents and young adults with isolated systolic hypertension. The risk of a cardiovascular events in such patients is similar to that of age-matched individuals without isolated systolic hypertension [31] and lower than those with combined systolic-diastolic hypertension or isolated diastolic hypertension [32, 33]. Indeed, young adults with isolated systolic hypertension appear to comprise a heterogeneous patients group, including those with increased stroke volume, normal central blood pressure but exaggerated blood pressure amplification from the central to the peripheral arteries, and those with accelerated vascular aging and premature arterial stiffness [34]. In these young patients, assessing arterial stiffness is even more indicated [35] as well as out-of-office blood pressure monitoring to exclude white-coat hypertension [36].

Supplementary information

Supplementary Information

Supplementary Table

Supplementary information

The online version contains supplementary material available at 10.1038/s41440-024-01779-4.

Acknowledgements

The authors gratefully acknowledge the expert clerical assistance of Mrs. Renilde Wolfs (Studies Coordinating Centre, Leuven, Belgium).

The International Database of Central Arterial Properties for Risk Stratification (IDCARS) Investigators

Lucas S. Aparicio14, Jessica Barochiner14, Blerim Mujaj15, Lutgarde Thijs15, Jan A. Staessen15, Fang-Fei Wei15, Wen-Yi Yang15, Zhen-Yu Zhang15, De-Wei An16, Yi-Bang Cheng16, Qian-Hui Guo16, Jian-Feng Huang16, Qi-Fang Huang16, Yuan-Yuan Kang16, Yan Li16, Chang-Yuan Liu16, Chang-Sheng Sheng16, Ji-Guang Wang16, Ying Wang16, Dong-Yan Zhang16, Wei Zhang16, Jan Filipovský17, Jitka Seidlerová17, Eeva P. Juhanoja18, Antti M. Jula18, Annika S. Lindroos18, Teemu J. Niiranen18, Sam S. Sivén18, Edoardo Casiglia19, Alessandra Pizziol19, Valérie Tikhonoff19, Babangida S. Chori20, Benjamin Danladi20, Augustine N. Odili20, Henry Oshaju20, Wiesława Kucharska21, Katarzyna Kunicka21, Natasza Gilis-Malinowska21, Krzysztof Narkiewicz21, Wojciech Sakiewicz21, Ewa Swierblewska21, Kalina Kawecka-Jaszcz22, Katarzyna Stolarz-Skrzypek22, Catharina M. C. Mels23, Ruan Kruger23, Gontse G. Mokwatsi23, Aletta E. Schutte23, Gavin R. Norton24, Angela Woodiwiss24, Daniel Ackermann25, Murielle Bochud25, Georg Ehret25, Ramón Álvarez-Vaz26, Anna C. Rios26, Florencia Carusso26, Mariana Sottolano26, José Boggia26, Luciana Borgarello26, Sebastián Robaina26, Paula Moliterno26, Oscar Noboa26, Alicia Olascoaga26, Alicia da Rosa26, Nadia Krul26, Matias Pécora26

Funding

Argentina: The Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Belgium: European Union (HEALTH-F7-305507 HOMAGE), European Research Council (Advanced Researcher Grant 2011-294713-EPLORE and Proof-of-Concept Grant 713601-uPROPHET), European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT) and Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium (G.0881.13); Belgium (APPREMED): The Research Institute Alliance for the Promotion of Preventive Medicine (URL: www.appremed.org) received a non-binding grant from OMRON Healthcare Co., Ltd., Kyoto, Japan; China: The National Natural Science Foundation of China (Grants 82270469, 82070432, 81970353), the Ministry of Science and Technology (2022YFC3601302), Beijing, China, and by the Shanghai Commissions of Science and Technology (Grants 19ZR1443300), and the Shanghai Municipal Health Commission (202340035, 20234Y0036, 201940297 and a Grant for Leading Academics 2022LJ022); Czech Republic: European Union (Grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550) and Charles University Research Fund (Project P36); Finland: Academy of Finland (Grant 321351), Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Urmas Pekkala Foundation, and the Hospital District of South-Western Finland; Italy: European Union (Grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550); Poland (Gdańsk): European Union (Grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550); Poland (Kraków): European Union (Grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550) and Foundation for Polish Science; Uruguay: Asociación Española Primera en Salud. Switzerland: Swiss National Science Foundation (FN 33CM30‐124087 and FN 33CM30‐140331). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Members of the International Database of Central Arterial Properties for Risk Stratification (IDCARS) Investigators are listed below Acknowledgements.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors jointly supervised this work: Yan Li, Jan A. Staessen.
==== Refs
References

1. Avolio AP Van Bortel LM Boutouyrie P Cockcroft JR McEniery CM Protogerou AD Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data Hypertension 2009 54 375 83 10.1161/HYPERTENSIONAHA.109.134379 19564542
Avolio AP, Van Bortel LM, Boutouyrie P, Cockcroft JR, McEniery CM, Protogerou AD, et al. Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension. 2009;54:375–83.19564542 10.1161/HYPERTENSIONAHA.109.134379
2. Benetos A Thomas F Joly L Blacher J Pannier B Labat C Pulse pressure amplification: a mechanical biomarker of cardiovascular risk J Am Coll Cardiol 2010 55 1032 37 10.1016/j.jacc.2009.09.061 20202520
Benetos A, Thomas F, Joly L, Blacher J, Pannier B, Labat C, et al. Pulse pressure amplification: a mechanical biomarker of cardiovascular risk. J Am Coll Cardiol. 2010;55:1032–37.20202520 10.1016/j.jacc.2009.09.061
3. Benetos A Gautier S Labat C Salvi P Valbusa F Marino F Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study J Am Coll Cardiol 2012 60 1503 11 10.1016/j.jacc.2012.04.055 22999729
Benetos A, Gautier S, Labat C, Salvi P, Valbusa F, Marino F, et al. Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study. J Am Coll Cardiol. 2012;60:1503–11.22999729 10.1016/j.jacc.2012.04.055
4. McEniery CM Cockcroft JR Roman MJ Franklin SS Wilkinson IB Central blood pressure: current evidence and clinical importance Eur Heart J 2014 35 1719 25 10.1093/eurheartj/eht565 24459197
McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35:1719–25.24459197 10.1093/eurheartj/eht565
5. Chirinos JA Segers P Hughes T Townsend R Large-artery stiffness in health and disease: JACC state-of-the-art review J Am Coll Cardiol 2019 74 1237 63 10.1016/j.jacc.2019.07.012 31466622
Chirinos JA, Segers P, Hughes T, Townsend R. Large-artery stiffness in health and disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:1237–63.31466622 10.1016/j.jacc.2019.07.012
6. Chirinos JA Segers P Noninvasive evaluation of left ventricular afterload: part 1: pressure and flow measurements and basic principles of wave conduction and reflection Hypertension 2010 56 555 62 10.1161/HYPERTENSIONAHA.110.157321 20733089
Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 1: pressure and flow measurements and basic principles of wave conduction and reflection. Hypertension. 2010;56:555–62.20733089 10.1161/HYPERTENSIONAHA.110.157321
7. McEniery CM Yasmin Hall IR Qasem A Wilkinson IB Cockcroft JR on behalf of the ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT) J Am Coll Cardiol 2005 46 1753 60 10.1016/j.jacc.2005.07.037 16256881
McEniery CM, Yasmin Hall IR, Qasem A, Wilkinson IB, Cockcroft JR, on behalf of the ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46:1753–60.16256881 10.1016/j.jacc.2005.07.037
8. Wassertheurer S Burkhardt K Heemann U Baumann M Aortic to brachial pulse pressure amplification as functional marker and predictor of renal function loss in chronic kidney disease J Clin Hypertens 2014 16 401 5 10.1111/jch.12316
Wassertheurer S, Burkhardt K, Heemann U, Baumann M. Aortic to brachial pulse pressure amplification as functional marker and predictor of renal function loss in chronic kidney disease. J Clin Hypertens. 2014;16:401–5.10.1111/jch.12316
9. Cho SW Kim BK Kim JH Byun YS Goh CW Rhee KJ Non-invasively measured aortic wave reflection and pulse pressure amplification are related to the severity of coronary artery disease J Cardiol 2013 62 131 37 10.1016/j.jjcc.2013.03.014 23731925
Cho SW, Kim BK, Kim JH, Byun YS, Goh CW, Rhee KJ, et al. Non-invasively measured aortic wave reflection and pulse pressure amplification are related to the severity of coronary artery disease. J Cardiol. 2013;62:131–37.23731925 10.1016/j.jjcc.2013.03.014
10. Aparicio LS Huang QF Melgarejo JD Wei DM Thijs L We FF The International Database of Central Arterial Properties for Risk Stratification: research objectives and baseline characteristics of participants Am J Hypertens 2021 35 54 64 10.1093/ajh/hpab139
Aparicio LS, Huang QF, Melgarejo JD, Wei DM, Thijs L, We FF, et al. The International Database of Central Arterial Properties for Risk Stratification: research objectives and baseline characteristics of participants. Am J Hypertens. 2021;35:54–64.10.1093/ajh/hpab139
11. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects J Am Med Ass 2013 310 2191 94 10.1001/jama.2013.281053
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Ass. 2013;310:2191–94.10.1001/jama.2013.281053
12. Pauca AL O’Rourke M Kon ND Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform Hypertension 2001 38 932 37 10.1161/hy1001.096106 11641312
Pauca AL, O’Rourke M, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001;38:932–37.11641312 10.1161/hy1001.096106
13. Levey AS Stevens LA Schmid CH Zhang Y Castro AF III Feldman HI A new equation to estimate glomerular filtration rate Ann Intern Med 2009 150 604 12 10.7326/0003-4819-150-9-200905050-00006 19414839
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.19414839 10.7326/0003-4819-150-9-200905050-00006
14. Schoenfeld DA Sample-size formula for proportional-hazards regression model Biometrics 1983 39 499 503 10.2307/2531021 6354290
Schoenfeld DA. Sample-size formula for proportional-hazards regression model. Biometrics. 1983;39:499–503.6354290 10.2307/2531021
15. Gu YM Thijs L Li Y Asayama K Boggia J Hansen TW Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations Hypertension 2014 63 229 37 10.1161/HYPERTENSIONAHA.113.02179 24324050
Gu YM, Thijs L, Li Y, Asayama K, Boggia J, Hansen TW, et al. Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. Hypertension. 2014;63:229–37.24324050 10.1161/HYPERTENSIONAHA.113.02179
16. Kikuya M Hansen TW Thijs L Björklund-Bodegård K Kuznetsova T Ohkubo T Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk Circulation 2007 115 2145 52 10.1161/CIRCULATIONAHA.106.662254 17420350
Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007;115:2145–52.17420350 10.1161/CIRCULATIONAHA.106.662254
17. Pencina MJ D’Agostino RB Sr D’Agostino RB Jr Vasan RS Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 2008 27 157 72 10.1002/sim.2929 17569110
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72.17569110 10.1002/sim.2929
18. Hosmer DW Jr, Leleshow S. Applied logistic regression. New York, USA: Wiley; 1989. pp. 47–56.
19. Mitchell GF Hwang SJ Vasan RS Larson MG Pencina MJ Hamburg NM Arterial stiffness and cardiovascular events: the Framingham Heart Study Circulation 2010 121 505 11 10.1161/CIRCULATIONAHA.109.886655 20083680
Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121:505–11.20083680 10.1161/CIRCULATIONAHA.109.886655
20. McEniery Yasmin CM McDonnell B Munnery M Wallace SM Rowe CV Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II Hypertension 2008 51 1476 82 10.1161/HYPERTENSIONAHA.107.105445 18426997
McEniery, Yasmin CM, McDonnell B, Munnery M, Wallace SM, Rowe CV, et al. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension. 2008;51:1476–82.18426997 10.1161/HYPERTENSIONAHA.107.105445
21. Li Y Staessen JA Sheng CS Huang QF O’Rourke M Wang JG Age dependency of peripheral and central systolic pressures: cross-sectional and longitudinal observations in a Chinese population Hypertens Res 2012 35 115 22 10.1038/hr.2011.160 21918523
Li Y, Staessen JA, Sheng CS, Huang QF, O’Rourke M, Wang JG. Age dependency of peripheral and central systolic pressures: cross-sectional and longitudinal observations in a Chinese population. Hypertens Res. 2012;35:115–22.21918523 10.1038/hr.2011.160
22. Wojciechowska W Staessen JA Nawrot T Cwynar M Sleidlerová J Stolarz K Reference values in White Europeans for the arterial pulse wave recorded by means of the ShygmoCor device Hypertens Res 2006 29 475 83 10.1291/hypres.29.475 17044659
Wojciechowska W, Staessen JA, Nawrot T, Cwynar M, Sleidlerová J, Stolarz K, et al. Reference values in White Europeans for the arterial pulse wave recorded by means of the ShygmoCor device. Hypertens Res. 2006;29:475–83.17044659 10.1291/hypres.29.475
23. Wilkinson IB Franklin SS Hall IR Tyrrell S Cockcroft JR Pressure amplification explains why pulse pressure is unrelated to risk in young subjects Hypertension 2001 38 1461 66 10.1161/hy1201.097723 11751736
Wilkinson IB, Franklin SS, Hall IR, Tyrrell S, Cockcroft JR. Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. Hypertension. 2001;38:1461–66.11751736 10.1161/hy1201.097723
24. O’Rourke MF Kim M Adji A Nichols WW Avolio A Use of arterial transfer function for the derivation of aortic wave characrteristics J Hypertens 2004 22 431 2 10.1097/00004872-200402000-00030 15076204
O’Rourke MF, Kim M, Adji A, Nichols WW, Avolio A. Use of arterial transfer function for the derivation of aortic wave characrteristics. J Hypertens. 2004;22:431–2.15076204 10.1097/00004872-200402000-00030
25. Segers P Mahieu D Kips J Van Bortel LM The use of a generalized transfer function: different processing, different results! J Hypertens 2007 25 1783 87 10.1097/HJH.0b013e3282ef5c5f 17762638
Segers P, Mahieu D, Kips J, Van Bortel LM. The use of a generalized transfer function: different processing, different results! J Hypertens. 2007;25:1783–87.17762638 10.1097/HJH.0b013e3282ef5c5f
26. Chen CH Nevo E Fetics B Pak PH Yin FC Maughan WL Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure: validation of generalized transfer function Circulation 1997 95 1827 36 10.1161/01.CIR.95.7.1827 9107170
Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure: validation of generalized transfer function. Circulation. 1997;95:1827–36.9107170 10.1161/01.CIR.95.7.1827
27. Sharman JE Lim R Qasem AM Coombes JS Burgess MI Franco J Validation of a generalized transfer function to noninvasively derived central blood pressure during exercise Hypertension 2006 47 1203 8 10.1161/01.HYP.0000223013.60612.72 16651459
Sharman JE, Lim R, Qasem AM, Coombes JS, Burgess MI, Franco J, et al. Validation of a generalized transfer function to noninvasively derived central blood pressure during exercise. Hypertension. 2006;47:1203–8.16651459 10.1161/01.HYP.0000223013.60612.72
28. Riley RD Lambert PC Abo-Zaid G Meta-analysis of individual participant data: rationale, conduct, and reporting Br Med J 2010 340 c221 10.1136/bmj.c221 20139215
Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. Br Med J. 2010;340:c221.20139215 10.1136/bmj.c221
29. Odili AN Chori BS Danladi B Yang WY Zhang ZY Thijs L Electrocardiographic left ventricular hypertrophy in relation to peripheral and central blood pressure indices in a Nigerian population Blood Press 2019 29 39 46 10.1080/08037051.2019.1646610 31352838
Odili AN, Chori BS, Danladi B, Yang WY, Zhang ZY, Thijs L, et al. Electrocardiographic left ventricular hypertrophy in relation to peripheral and central blood pressure indices in a Nigerian population. Blood Press. 2019;29:39–46.31352838 10.1080/08037051.2019.1646610
30. Staessen J Amery A Fagard R Editorial review. Isolated systolic hypertension in the elderly J Hypertens 1990 8 393 405 10.1097/00004872-199005000-00001 2163412
Staessen J, Amery A, Fagard R. Editorial review. Isolated systolic hypertension in the elderly. J Hypertens. 1990;8:393–405.2163412 10.1097/00004872-199005000-00001
31. Eeftinck Schattenkerk DW van Gorp J Vogt L Peters RJG van den Born BJH Isolated systolic hypertension of the young and its association with central blood pressure in a large multi-ethnic population: the HELIUS study Eur J Prev Cardiol 2018 25 1351 59 10.1177/2047487318777430 29808754
Eeftinck Schattenkerk DW, van Gorp J, Vogt L, Peters RJG, van den Born BJH. Isolated systolic hypertension of the young and its association with central blood pressure in a large multi-ethnic population: the HELIUS study. Eur J Prev Cardiol. 2018;25:1351–59.29808754 10.1177/2047487318777430
32. Saladini F Fania C Mos L Mazzer A Casiglia E Palatini P Office pulse pressure is a predictor of favorable outcome in young- to middle-aged subjects with stage 1 hypertension Hypertension 2017 70 537 42 10.1161/HYPERTENSIONAHA.117.09516
Saladini F, Fania C, Mos L, Mazzer A, Casiglia E, Palatini P. Office pulse pressure is a predictor of favorable outcome in young- to middle-aged subjects with stage 1 hypertension. Hypertension. 2017;70:537–42.10.1161/HYPERTENSIONAHA.117.09516
33. Yao Y Stamler J Garside DB Daviglus ML Franklin SS Cernethon MR Isolated systolic hypertension in young and middle-aged adullts and 31-year risk for cardiovasvular mortality J Am Coll Cardiol 2015 65 327 35 10.1016/j.jacc.2014.10.060 25634830
Yao Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Cernethon MR, et al. Isolated systolic hypertension in young and middle-aged adullts and 31-year risk for cardiovasvular mortality. J Am Coll Cardiol. 2015;65:327–35.25634830 10.1016/j.jacc.2014.10.060
34. McEniery Yasmin CM Wallace S Maki-Petaya K McDonnell B Sharman JE Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults Hypertension 2005 46 221 26 10.1161/01.HYP.0000165310.84801.e0 15867140
McEniery, Yasmin CM, Wallace S, Maki-Petaya K, McDonnell B, Sharman JE, et al. Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension. 2005;46:221–26.15867140 10.1161/01.HYP.0000165310.84801.e0
35. Palatini P Rosei EA Avolio A Bilo G Casiglia E Ghiadoni L Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension J Hypertens 2018 36 1222 36 10.1097/HJH.0000000000001726 29570514
Palatini P, Rosei EA, Avolio A, Bilo G, Casiglia E, Ghiadoni L, et al. Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. J Hypertens. 2018;36:1222–36.29570514 10.1097/HJH.0000000000001726
36. Asayama K Stolarz-Skrzypek K Yang WY Hansen TW Brguljan-Hitij J Odili AN What did we learn from the international databases on ambulatory and home blood pressure in relation to cardiovascular outcome? Hypertens Res 2023 46 934 49 10.1038/s41440-023-01191-4 36737461
Asayama K, Stolarz-Skrzypek K, Yang WY, Hansen TW, Brguljan-Hitij J, Odili AN, et al. What did we learn from the international databases on ambulatory and home blood pressure in relation to cardiovascular outcome? Hypertens Res. 2023;46:934–49.36737461 10.1038/s41440-023-01191-4
